Charles Mullighan's guest appearances

Charles Mullighan

17th European Haematology Association (EHA) Congress

John Porter

Michael Keating

Jan Geissler

Willem Fibbe

Jing Chen

Mark Frattini

Giora Sharf

OwlTail

Dr Mullighan talks to ecancer at the European Hematology Association congress 2012. Whole genome sequence analysis of MLL-rearranged infant ALL has revealed remarkably few mutations in a study from the St Jude Children's Research Hospital and Washington University Pediatric Cancer Genome Project. (MLL = Myeloid/lymphoid or mixed-lineage leukemia gene)A small number of genetic changes are needed to drive this disease, meaning epigenetic approaches may be therapeutically beneficial. BCR-ABL-like leukaemia is also discussed, and better screening for patients at diagnosis. Whole genome sequencing for ALL is still in the early stages, but in the next few years enough should be understood to put new therapies in the clinic.

Dr Mullighan talks to ecancer at the European Hematology Association congress 2012. Whole genome sequence analysis of MLL-rearranged infant ALL has revealed remarkably few mutations in a study from the St Jude Children's Research Hospital and Washington University Pediatric Cancer Genome Project. (MLL = Myeloid/lymphoid or mixed-lineage leukemia gene) A small number of genetic changes are needed to drive this disease, meaning epigenetic approaches may be therapeutically beneficial. BCR-ABL-like leukaemia is also discussed, and better screening for patients at diagnosis. Whole genome sequencing for ALL is still in the early stages, but in the next few years enough should be understood to put new therapies in the clinic.

Whole genome sequence analysis for acute lymphoblastic leukaemia: Dr Charles Mullighan - St Jude Children's Research Hospital